CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

Neutral
AI Analysis

Summary

Morgan Stanley reduced its price target on Immix Biopharma from $20 to $19 while maintaining an Overweight rating.

Importance:2/10
Sentiment:
-0.20
price_targetanalyst_ratingstock_adjustment
Related Companies

Read the original article

Published by yahoo_finance on August 11, 2026 9:31 AM

Read Original